{
  "meta": {
    "title": "Mini_Test-_3_Problem_Solving_Staging",
    "url": "https://brainandscalpel.vercel.app/mini-test-3-problem-solving-staging-1e0b1bd3.html",
    "scrapedAt": "2025-11-30T12:37:39.125Z"
  },
  "questions": [
    {
      "text": "A 2-year-old baby weighing 15 kg was brought to the hospital with a history of loose stools. He is afebrile, and there is no blood in his stools. The baby is lethargic. On examination, eyes are sunken and during the skin pinch test, the skin retraction took more than two seconds. On offering water the child doesn't show eagerness to drink and responds poorly. Which of the following is correct with respect to the treatment of dehydration in this child?",
      "choices": [
        {
          "id": 1,
          "text": "600 ml to be given as IV in the first 1 hour"
        },
        {
          "id": 2,
          "text": "Zinc, antibiotics, and oral rehydration solution"
        },
        {
          "id": 3,
          "text": "450 ml to be given as IV in the first half hour"
        },
        {
          "id": 4,
          "text": "450 ml to be given as IV in the first 1 hour"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The child in this scenario has <strong>severe dehydration</strong>, as indicated by lethargy, sunken eyes, and the skin goes back slowly on the skin pinch test (&gt;2 seconds).</p>\n<p>Severe dehydration requires <strong>treatment plan C</strong>. This involves using <strong>intravenous fluids</strong> (ringer lactate with 5% dextrose).</p>\n<p>100ml/kg of fluid should be given over 3 hours in children of age more than 12 months. For those who are less than 12 months old, the fluid should be given over 6 hours.</p>\n<p>Fluid requirement for severe dehydration is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td>Age</td>\n<td>30 mL/kg</td>\n<td>70 mL/kg</td>\n</tr>\n<tr>\n<td>&lt;12 months</td>\n<td>1 hr</td>\n<td>5 hr</td>\n</tr>\n<tr>\n<td>&gt;12 months</td>\n<td>30 min</td>\n<td>2.5 hr</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<p>Calculation of fluid required: The baby requires 30 mL/kg fluid and the weight of the baby is 15 kg. </p>\n<p>Therefore, the total fluid requirement is: </p>\n<p>15 kg x 30 mL/kg = <strong>450 ml fluids in the first half-hour,</strong> and</p>\n<p>15 kg x 70 mL/kg = <strong>1050 ml over the next 2.5 hours.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2855",
      "difficulty": "hard"
    },
    {
      "text": "A 10-day-old female neonate with hypoxic-ischemic encephalopathy (HIE) is hyper-alert with normal EEG. Examination shows hyperactive tendon reflexes, mydriatic pupil, and clonus.  What stage of HIE is she in?",
      "choices": [
        {
          "id": 1,
          "text": "Stage 1"
        },
        {
          "id": 2,
          "text": "Stage 2"
        },
        {
          "id": 3,
          "text": "Stage 3"
        },
        {
          "id": 4,
          "text": "Stage 4"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>According to <strong>Sarnat staging</strong> of <strong>hypoxic-ischemic encephalopathy</strong> (HIE), a <strong>hyperalert</strong> neonate with <strong>mydriatic pupil</strong>, hyperactive tendon reflex, <strong>clonus</strong>, and <strong>normal EEG</strong> belongs to <strong>stage</strong> <strong>1</strong>.&nbsp;</p>\n<p>HIE is a brain injury that <strong>prevents adequate blood supply to the infant's brain</strong>.&nbsp;</p>\n<p>Sarnat staging of HIE:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Signs</strong></td>\n<td><strong>Stage 1</strong></td>\n<td><strong>Stage 2</strong></td>\n<td><strong>&nbsp;Stage 3</strong></td>\n</tr>\n<tr>\n<td><strong>Level of consciousness</strong></td>\n<td><strong>Hyperalert</strong></td>\n<td>Lethargic</td>\n<td>Stuporous, comatose</td>\n</tr>\n<tr>\n<td><strong>Muscle tone</strong></td>\n<td>Normal</td>\n<td>Hypotonic</td>\n<td>Flaccid</td>\n</tr>\n<tr>\n<td><strong>Posture</strong></td>\n<td>Normal</td>\n<td>Flexion</td>\n<td>Decerebrate</td>\n</tr>\n<tr>\n<td><strong>Tendon reflex/clonus</strong></td>\n<td><strong>Hyperactive</strong></td>\n<td>Hyperactive</td>\n<td>Absent</td>\n</tr>\n<tr>\n<td><strong>Myoclonus</strong></td>\n<td>Present</td>\n<td>Present</td>\n<td>Absent</td>\n</tr>\n<tr>\n<td><strong>Moro reflex</strong></td>\n<td>Strong</td>\n<td>Weak</td>\n<td>Absent</td>\n</tr>\n<tr>\n<td><strong>Pupils</strong></td>\n<td><strong>Mydriasis</strong></td>\n<td>Miosis</td>\n<td>Unequal, poor light reflex</td>\n</tr>\n<tr>\n<td><strong>Seizures</strong></td>\n<td>None</td>\n<td>Common</td>\n<td>Decerebration</td>\n</tr>\n<tr>\n<td><strong>EEG findings</strong></td>\n<td><strong>Normal</strong></td>\n<td>Low voltage changing to seizure activity</td>\n<td>\n<p>Burst suppression to isoelectric</p>\n</td>\n</tr>\n<tr>\n<td><strong>Duration</strong></td>\n<td>&lt;24 hours if progress it; otherwise, can remain normal</td>\n<td>24 hours to 14 days</td>\n<td>Days to weeks</td>\n</tr>\n<tr>\n<td><strong>Outcome</strong></td>\n<td>Good</td>\n<td>Variable</td>\n<td>Death, severe deficits</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Maternal<strong>&nbsp;</strong>causes for HIE are&nbsp;hypoventilation during anesthesia, cyanotic heart disease, respiratory failure, or carbon monoxide poisoning. Failure of oxygenation due to severe anemia, massive blood loss, and intracranial or adrenal hemorrhages are fetal causes of HIE.&nbsp;</p>\n<p>Hypoxia and ischemia cause <strong>anaerobic metabolism</strong> that generates a large amount of <strong>lactate and inorganic phosphates&nbsp;</strong>accumulation of toxic byproducts and overactivation of receptors. This leads to increased cellular permeability to sodium and calcium ions, resulting in cytotoxic edema and neuronal death.&nbsp;The most sensitive imaging modality for detecting hypoxic brain injury in neonates is an <strong>MRI</strong>.</p>\n<p><strong>Therapeutic hypothermia</strong> within the first 6 hours of life reduces mortality and major neurodevelopmental impairment. <strong>High-dose erythropoietin</strong> is used as an adjuvant to therapeutic hypothermia. Antiepileptic medications like phenobarbital and levetiracetam can be used to treat seizures.&nbsp;</p>\n<p>&nbsp;<strong>Poor prognostic factors</strong> in HIE are:</p>\n<ul>\n<li>Initial blood ph less than 6.7</li>\n<li>Low (0-3) 10&nbsp; in Apgar score</li>\n<li>Delayed onset of spontaneous breathing</li>\n<li>Seizure onset in less than 12 hours</li>\n<li>Burst suppression pattern in EEG</li>\n<li>Basal ganglia or thalamic lesion</li>\n<li>Oliguria or anurias for more than 24 hours</li>\n<li>Decerebrate posture</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC0222",
      "difficulty": "hard"
    },
    {
      "text": "A patient has presented for a routine eye evaluation. The minimum angle of resolution (MAR) in this patient is 2 minutes of arc. Which of the following correctly represents the visual acuity of this patient measured using Snellen's chart?",
      "choices": [
        {
          "id": 1,
          "text": "6/36"
        },
        {
          "id": 2,
          "text": "6/12"
        },
        {
          "id": 3,
          "text": "6/60"
        },
        {
          "id": 4,
          "text": "6/6"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The visual acuity in this patient according to Snellen's chart is <strong>6/12</strong>.</p>\n<p>The <strong>minimum</strong> <strong>angle</strong> <strong>of</strong> <strong>resolution </strong>(MAR) is a measure of visual acuity calculated by dividing the denominator of Snellen's fraction by the distance at which it was read- i.e, the <strong>Snellen's fraction is inverted and reduced. </strong>The formula is as follows:</p>\n<p><em>MAR= 1/Visual acuity</em></p>\n<p><em>Then Visual acuity = 1/MAR</em></p>\n<p><em>Since in this patient, the MAR is given as 2 minutes of arc, visual acuity = 1/2. In order to represent </em><em>the visual acuity with the numerator of 6, 1/2 can be written as <strong>6/12</strong>.</em></p>\n<p>Visual acuity is a measure of the spatial resolution of the eye or an estimation of its ability to discriminate between two points.</p>\n<p>Snellen's chart consists of a series of letters arranged in lines, each diminishing in size such that at the <strong>nodal</strong> <strong>point</strong> of the eye at the given distance</p>\n<ul>\n<li>The minimum angle of resolution is<strong> 1 minute of arc</strong></li>\n<li>Each whole letter will subtend an <strong>angle of 5 minutes</strong>.</li>\n</ul>\n<p>In the Snellen chart, the largest letter will subtend an angle of 5 minutes at the nodal point if it is 60 m from the eye. Those in the subsequent lines will subtend an angle of 5 minutes if they are 36, 24, 18, 12, 9, and 6 m from the eye.</p>\n<p>Other options:</p>\n<p>Option A: For acuity of <strong>6/36</strong>, MAR = 36/6 = <strong>6 minutes of arc</strong></p>\n<p>Option C: For acuity of<strong> 6/60</strong>, MAR = 60/6 = <strong>10 minutes of arc</strong></p>\n<p>Option D: For acuity of <strong>6/6</strong>, MAR = 6/6 = <strong>1 minutes of arc</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/192387686eb2481ca5231f8af8a9f6c6x1280x1482.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2774",
      "difficulty": "medium"
    },
    {
      "text": "A 55-year-old woman is diagnosed to have cervical cancer. MRI and PET-CT imaging reveal tumour extension up to the pelvic wall and involvement of the para-aortic lymph nodes. It also shows features suggestive of hydronephrosis. Which stage is it according to the FIGO staging of cervical cancer?<div class='question-desc-html'><p>PET-CT - Positron Emission Tomography/Computed Tomography<br />FIGO - International Federation of Gynecology and Obstetrics</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Stage III B"
        },
        {
          "id": 2,
          "text": "Stage III C1"
        },
        {
          "id": 3,
          "text": "Stage III C2"
        },
        {
          "id": 4,
          "text": "Stage IV A"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Cervical cancer involving the <strong>para-aortic lymph nodes</strong> is classified as <strong>Stage III C2</strong> according to FIGO staging.</p>\n<p>Cervical cancer is the most common gynecological cancer. The FIGO staging uses clinical, radiological, or pathological findings to stage cervical cancer from Stage I to IV.</p>\n<p><strong>Stage III</strong> cervical carcinoma involves the lower 1/3rd of the vagina, with or without <strong>pelvic wall extension</strong>, <strong>hydronephrosis</strong>, and <strong>lymph node</strong> involvement. It is further staged as follows:</p>\n<ul class=\"unordered-list\">\n<li>Stage III A: Lower 1/3rd of the vagina involvement, no pelvic wall extension</li>\n<li>Stage III B:&nbsp;Pelvic wall involvement with or without hydronephrosis or a non-functioning kidney</li>\n<li>Stage III C:&nbsp;Involvement of the pelvic and/or paraaortic lymph nodes\n<ul>\n<li>Stage III C1<strong>: </strong>Metastasis to&nbsp;pelvic lymph node only</li>\n<li><strong>Stage III C2: </strong>Metastasis to <strong>para-aortic lymph nodes</strong></li>\n</ul>\n</li>\n</ul>\n<p>Note: If the carcinoma had extended beyond the true pelvis, involving adjacent pelvic organs like the bladder or rectum, it would've been classified as Stage IV A.</p><hr><h3>Related Pearl: Staging of Carcinoma Cervix</h3><p><strong>Stage I - limited to the cervix</strong></p>\n<ul>\n<li>A: Microscopic lesion\n<ul>\n<li>A1 - stromal invasion &lt;3mm depth</li>\n<li>A2 - a stromal invasion of &ge;3 and &lt;5mm depth</li>\n</ul>\n</li>\n<li>B: Macroscopic lesion\n<ul>\n<li>B1 - stromal invasion &ge;5mm depth &amp; tumor size &lt;2cm&nbsp;</li>\n<li>B2 - tumor size &ge;2cm to &lt;4cm&nbsp;</li>\n<li>B3 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage II - involves upper 2/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to the upper two-thirds of the vagina without parametrial involvement\n<ul>\n<li>A1 - tumor size &lt;4cm&nbsp;</li>\n<li>A2 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n<li>B: Extends to parametrium but not upto the pelvic wall.</li>\n</ul>\n<p><strong>Stage III - spreads to lower 1/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to lower 1/3 of the vagina</li>\n<li>B: Extends to the pelvic wall (hydronephrosis/non-functioning kidney)</li>\n<li>C: Involvement of the pelvic and/or para-aortic lymph nodes, irrespective of the tumor size and extent\n<ul>\n<li>C1: pelvic lymph node involved</li>\n<li>C2: para-aortic lymph node&nbsp;involved</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage IV - metastasis</strong></p>\n<ul>\n<li>A: Bladder/bowel involvement (adjacent pelvic organs)</li>\n<li>B: Distant metastasis</li>\n</ul>\n<p>Note:&nbsp;The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.</p>\n<p>Stage IIIB is the most common stage of presentation.</p><hr><h3>Related Pearl: General treatment for primary invasive cervical carcinoma</h3><table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>Fertility preserved</strong></td>\n<td><strong>Fertility not preserved</strong></td>\n</tr>\n<tr>\n<td>IA1</td>\n<td>Cervical conization</td>\n<td>Simple hysterectomy</td>\n</tr>\n<tr>\n<td>IA1 (LVSI)</td>\n<td>Radical trachelectomy and pelvic lymphadenectomy</td>\n<td>Modified radical hysterectomy and pelvic lymphadenectomy</td>\n</tr>\n<tr>\n<td>IA2</td>\n<td>\n<p>1. Cervical conization with extraperitoneal pelvic lymphadenectomy</p>\n<p>2. Radical trachelectomy and pelvic lymphadenectomy</p>\n</td>\n<td>Modified Radical hysterectomy and pelvic lymphadenectomy</td>\n</tr>\n<tr>\n<td>\n<p>IB1</p>\n<p>Some IB2, IIA1</p>\n</td>\n<td>Radical trachelectomy and pelvic lymphadenectomy (or)chemoradiation</td>\n<td>Radical hysterectomy and pelvic lymphadenectomy (or) chemoradiation</td>\n</tr>\n<tr>\n<td>Bulky IB3, IIA2</td>\n<td colspan=\"2\">Chemoradiation</td>\n</tr>\n<tr>\n<td>IIB to IVA</td>\n<td colspan=\"2\">Chemoradiation or pelvic exenteration&nbsp;</td>\n</tr>\n<tr>\n<td>IVB</td>\n<td colspan=\"2\">Palliative chemotherapy or palliative radiotherapy or supportive care</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC0152",
      "difficulty": "medium"
    },
    {
      "text": "A 51-year-old lady presents with complaints of a mass in the right breast. On examination, the mass was larger than 2cm and ipsilateral mobile axillary lymph nodes were present. What is the staging, considering the mass is malignant?",
      "choices": [
        {
          "id": 1,
          "text": "cT4N1M0"
        },
        {
          "id": 2,
          "text": "yT4N1M0"
        },
        {
          "id": 3,
          "text": "cT3N1M0"
        },
        {
          "id": 4,
          "text": "yT3N1M0"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The clinical scenario of a 51-year-old lady with a breast mass &gt;2cm, lymph node involvement (N1), and the image showing <strong>an ulcerative mass near the nipple </strong>of the right breast (T4), is clinically suggestive of <strong>inflammatory breast carcinoma. </strong>Its likely staging is<strong> cT4N1M0</strong></p>\n<p><strong>Inflammatory breast carcinoma</strong> (stage <strong>T4</strong>) is an <strong>aggressive</strong> form of <strong>locally advanced breast cancer (LABC)</strong> and is associated with the <strong>worst prognosis </strong>among all subtypes of breast cancer. It accounts for &lt;3% of breast cancers. It is characterized by skin changes of brawny induration, erythema, and edema (peau d’orange). The term <strong>peau d’orange</strong> describes the orange-peel appearance of the skin resulting from edema and dimpling at sites of hair follicles.</p>\n<p>In order to determine the best course of treatment for a patient with IBC, it is important to stage cancer. Staging is the process of determining the extent to which cancer has spread within the breast and to other parts of the body. Some prefixes and suffixes are used with the<strong> cTNM (clinical)</strong> and pTNM (pathologic) staging systems to designate special cases. These do not affect the stage group but indicate that they must be analyzed separately. The <strong>“y” prefix,</strong> denotes patients who have <strong>received systemic therapy before surgery.</strong> In this patient, since the staging is being done clinically, \"c\" is added as a prefix. </p>\n<p>The diagnostic criteria for inflammatory breast cancer are - </p>\n<ul>\n<li>\n<p class=\"bulletIndent1\"><strong>Rapid</strong> onset of breast <strong>erythema</strong>, <strong>edema</strong> and/or <strong>peau d’orange</strong>, and/or <strong>warm</strong> breast (with or without an underlying palpable mass)</p>\n</li>\n<li>\n<p class=\"bulletIndent1\">Duration of history no more than <strong>six months</strong></p>\n</li>\n<li>\n<p class=\"bulletIndent1\">Erythema occupies at least <strong>one-third</strong> of the breast</p>\n</li>\n<li>\n<p class=\"bulletIndent1\">Pathologic confirmation of <strong>invasive</strong> carcinoma</p>\n</li>\n</ul>\n<div class=\"page\" title=\"Page 883\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The pathologic <strong>hallmark</strong> is the presence of <strong>tumor cells</strong> within <strong>dermal lymphatics</strong> in skin biopsy specimens, but it is not a prerequisite for diagnosis.</p>\n<div class=\"page\" title=\"Page 883\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mammography may be normal or show <strong>skin thickening</strong>. A PET-CT scan should be considered at the time of diagnosis to rule out concurrent metastatic disease.</p>\n<p><strong>Axillary nodal</strong> metastases are common, and there is a significant risk for <strong>distant metastases</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n<p><strong>Combined-modality treatment</strong> is used, which includes</p>\n<ul>\n<li><strong>Neoadjuvant chemo­therapy</strong></li>\n<li><strong>Modified radical mastectomy</strong></li>\n<li><strong>Radiation therapy</strong></li>\n<li><strong>Hormonal</strong> therapy (for <strong>ER-positive</strong> tumors)</li>\n<li>Trastuzumab (for <strong>HER-2-positive</strong> tumors)</li>\n</ul>\n<p> </p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: TNM Staging of carcinoma breast</h3><table>\n<tbody>\n<tr>\n<td><strong>Tumor (T)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>Tis</td>\n<td>Ductal carcinoma in situ / Paget's disease</td>\n</tr>\n<tr>\n<td>T1</td>\n<td>\n<p><strong>&le;</strong><strong>2 cm</strong> in greatest dimension</p>\n<p>1a &gt;0.1 to 0.5 cm</p>\n<p>1b &gt;0.5 to 1 cm</p>\n<p>1c &gt;1 to 2 cm</p>\n</td>\n</tr>\n<tr>\n<td>T2</td>\n<td><strong>&gt;2 but &le;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T3</td>\n<td><strong>&gt;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T4</td>\n<td>\n<p>Tumor of<strong> any size&nbsp;</strong>and -</p>\n<p><strong>4a</strong> &ndash; chest wall involvement (except pectoralis major)<strong>#</strong>&nbsp;</p>\n<p><strong>4b </strong>&ndash; skin involvement in the form of ulceration, peau d&rsquo;orange, satellite nodules &nbsp;</p>\n<p><strong>4c </strong>&ndash; 4a + 4b &nbsp;</p>\n<p><strong>4d</strong> &ndash; inflammatory breast carcinoma(typical skin changes involving <span>&gt;</span>1/3rd of breast)<strong>*</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Nodes (N)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>N1 mic</td>\n<td>Refers to micrometastasis to Lymph node</td>\n</tr>\n<tr>\n<td>N1</td>\n<td>Ipsilateral <strong>mobile</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2A</td>\n<td>Ipsilateral<strong> fixed or matted</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2B</td>\n<td>Ipsilateral internal mammary <strong>without axillary lymph node</strong> involvement</td>\n</tr>\n<tr>\n<td>N3A</td>\n<td>Ipsilateral infraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td>N3B</td>\n<td>Ipsilateral internal mammary and axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N3C</td>\n<td>Ipsilateral supraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td><strong>Distant metastasis (M)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>Metastasis absent</td>\n<td>M0</td>\n</tr>\n<tr>\n<td>Metastasis present</td>\n<td>M1</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> T , N</strong></td>\n<td>&nbsp;<strong>M</strong></td>\n</tr>\n<tr>\n<td>Stage 0</td>\n<td>T<sub>is</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IA</td>\n<td>T<sub>1</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IB</td>\n<td>T<sub>0,1</sub>N<sub>1mic</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIA</td>\n<td>T<sub>0,1</sub>N<sub>1</sub> (or) T<sub>2</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIB</td>\n<td>T<sub>2</sub>N<sub>1</sub> (or) T<sub>3</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIA</td>\n<td>T<sub>0,1,2,3</sub>N<sub>2 </sub>(or) T<sub>3</sub>N<sub>1</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIB</td>\n<td><strong>T</strong><sub><strong>4</strong>&nbsp;</sub>N<sub>0,1,2</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIC</td>\n<td>\n<p>Any T,<strong> N<sub>3</sub></strong></p>\n</td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IV</td>\n<td>\n<p>Any T, Any N</p>\n</td>\n<td><strong>M<sub>1</sub></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>#</strong>Chest wall includes Serratus anterior, Intercostal muscles, Ribs.&nbsp;Pectoralis muscle is not a part of chest wall.</p>\n<p><strong>*</strong>Inflammatory breast carcinoma (stage IIIB) is characterized by the skin changes of&nbsp;<strong>brawny induration, erythema</strong> with a raised edge, and edema (<strong>peaud&rsquo;orange</strong>) involving <span>&gt;</span>1/3rd of breast.</p>\n<p><strong>Note:</strong> LCIS (lobular carcinoma in situ) is considered as a benign condition and not included under Tis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/67d205eb6e2245299a4229a459fd4e0bx401x170.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/fab6c0b7a5964d55bda87d9d63c4d1b8.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FB9242",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following staging systems is used for rectal carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Dukes staging"
        },
        {
          "id": 2,
          "text": "Bloom-Richardson grading"
        },
        {
          "id": 3,
          "text": "Nevine staging"
        },
        {
          "id": 4,
          "text": "Robson staging"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Dukes staging</strong> is used in rectal carcinoma.</p>\n<p><strong>Modified Dukes classification</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>A</p>\n</td>\n<td>\n<p>Growth limited to the rectal mucosa</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>B</p>\n</td>\n<td>\n<p>Growth extending to extrarectal tissues, but no lymphatic spread</p>\n<p>B1: Invading submucosa</p>\n<p>B2: Invading muscle layer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>C</p>\n</td>\n<td>\n<p>Lymph node secondaries</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>D</p>\n</td>\n<td>\n<p>Distant spread</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;<strong>Astler-Coller staging:</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>A</p>\n</td>\n<td>\n<p>Intramucosal lesions</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>B1</p>\n</td>\n<td>\n<p>Lesions extending into the muscularis propria, but not penetrating it, with negative nodes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>B2</p>\n</td>\n<td>\n<p>Lesions penetrating the muscularis propria, with negative nodes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>C1</p>\n</td>\n<td>\n<p>Lesions extending into the muscularis propria, but not penetrating it, with positive nodes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>C2</p>\n</td>\n<td>\n<p>Lesions penetrating the muscularis propria with positive nodes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>D</p>\n</td>\n<td>\n<p>Distant spread</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/47e1db89a4e348d5bff23ccb79e35475x1280x1193.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Important Tumor Classifications</h3><table>\n<tbody>\n<tr>\n<td><strong>Name of classification</strong>&nbsp;</td>\n<td><strong>Associated tumors</strong></td>\n</tr>\n<tr>\n<td>Bloom&ndash;Richardson grading</td>\n<td>Carcinoma breast</td>\n</tr>\n<tr>\n<td>Butchart staging</td>\n<td>Mesothelioma</td>\n</tr>\n<tr>\n<td>Chang staging</td>\n<td>Medulloblastoma</td>\n</tr>\n<tr>\n<td>Duke staging</td>\n<td>Colorectal carcinoma</td>\n</tr>\n<tr>\n<td>Gleason</td>\n<td>Prostate</td>\n</tr>\n<tr>\n<td>Jackson</td>\n<td>Carcinoma penis</td>\n</tr>\n<tr>\n<td>Masaoka staging</td>\n<td>Thymoma</td>\n</tr>\n<tr>\n<td>Noguchi</td>\n<td>Adenocarcinoma lung</td>\n</tr>\n<tr>\n<td>Nevine staging</td>\n<td>Carcinoma gall bladder</td>\n</tr>\n<tr>\n<td>Robson staging</td>\n<td>Renal cell carcinoma</td>\n</tr>\n<tr>\n<td>\n<div data-canvas-width=\"270.5335555427418\">Reiss and Ellsworth classification</div>\n<div data-canvas-width=\"190.96402760564516\">Esson prognostic index</div>\n</td>\n<td>Retinoblastoma</td>\n</tr>\n<tr>\n<td>Shimda index</td>\n<td>Neuroblastoma</td>\n</tr>\n<tr>\n<td>Sullivan modification of Macfarlane system</td>\n<td>Adrenocortical carcinoma</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC0079",
      "difficulty": "medium"
    },
    {
      "text": "The serum electrolyte values of a patient weighing 60kg are given below. Calculate the sodium deficit in the patient. \npH: 7.42, Na+: 120 mEq/L, serum K+: 4 mEq/L, serum Cl-: 90 mEq/L.",
      "choices": [
        {
          "id": 1,
          "text": "20 mEq"
        },
        {
          "id": 2,
          "text": "200 mEq"
        },
        {
          "id": 3,
          "text": "400 mEq"
        },
        {
          "id": 4,
          "text": "720 mEq"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The sodium deficit is calculated as<strong> (target sodium concentration-current sodium concentration) x 0.6 x Body weight</strong> (kg).</p>\n<p>Substituting the values, sodium deficit = (140-120) x 0.6 x 60 = <strong>720 mEq.</strong></p>\n<p>To calculate the<strong> sodium deficit</strong> in the patient, we first need to determine the <strong>target sodium concentration</strong> and compare it to the <strong>current sodium concentration.</strong></p>\n<p>The target sodium concentration can be calculated using the following formula:<br /><strong>Target Na concentration  = (Lower limit of serum sodium concentration + upper limit of serum sodium concentration) / 2</strong></p>\n<p>In this case, we assume the lower limit for the serum sodium concentration is 135 mEq/L, and the upper limit is 145 mEq/L.</p>\n<p>Target Na concentration = (135 + 145) / 2=<strong> 140 mEq/L</strong></p>\n<p>Next, the current sodium deficit can be calculated using the following formula:<br /><strong>Sodium Deficit = (Target sodium concentration-current sodium concentration) x Total Body Water (TBW) </strong></p>\n<p>Total Body Water (TBW) = Weight (in kg) × 0.6 (assuming 60% of body weight is water); TBW = 60 × 0.6= <strong>36 liters</strong></p>\n<p><strong>Sodium Deficit</strong> = (140 - 120) x 36 = 20 x 36 = <strong>720 mEq</strong></p>\n<p>Therefore, the sodium deficit in the patient is 720 mEq.</p>\n<p><strong>Rapid sodium correction</strong> of 4–6 mEq/L should be achieved in the<strong> first 6 hours</strong> of therapy for patients with<strong> acute hyponatremia.</strong></p>\n<p>The rate of correction should be comparatively <strong>slow</strong> in <strong>chronic hyponatremia:</strong> <strong>&lt;6-8 mEq/L</strong> in the <strong>first 24 h</strong> and &lt;6 mEq/L each subsequent 24h, so as to avoid <strong>osmotic demyelination syndrome.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2852",
      "difficulty": "hard"
    },
    {
      "text": "You are examining an 18-year-old woman and it appears she has mature adult breasts. What is the Tanner stage of breast development in her?",
      "choices": [
        {
          "id": 1,
          "text": "B3"
        },
        {
          "id": 2,
          "text": "B4"
        },
        {
          "id": 3,
          "text": "B5"
        },
        {
          "id": 4,
          "text": "B6"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The Tanner staging of the breast, in case of&nbsp;<strong>mature adult breast</strong>, is&nbsp;denoted as <strong>B5.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a2f85c615af24383ae28988489a999d5x1280x3776.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC0161",
      "difficulty": "medium"
    },
    {
      "text": "While examining a pregnant woman, you measure her fundal height to be 32 cm and the station of the fetal head is at -2. What could be the probable weight of the fetus?",
      "choices": [
        {
          "id": 1,
          "text": "2.3Kg"
        },
        {
          "id": 2,
          "text": "3.5Kg"
        },
        {
          "id": 3,
          "text": "3.1Kg"
        },
        {
          "id": 4,
          "text": "4.0Kg"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The fetal weight in the above case is<strong> 3.1Kg.</strong></p>\n<p>In the above case, fetal weight can be estimated using <strong>Johnson's formula</strong>. Height of uterus is 32cm, the station is –2 implying the head is above the ischial spines. Therefore, it is calculated as follows: [32-12] x 155 = 3100 grams = 3.1Kg</p>\n<p>Estimation of fetal weight:</p>\n<ul>\n<li><strong>Johnson’s formula: </strong>This is only applicable in vertex presentation.\n<ul>\n<li>If station of head is <strong>below</strong> the level of the ischial spine: [Height of uterus above pubic symphysis (in cm)<strong>-11</strong>] x 155 in grams</li>\n<li>If station of head is <strong>above</strong> the level of the ischial spine: [Height of uterus above pubic symphysis (in cm)<strong>-12</strong>] x 155 in grams</li>\n</ul>\n</li>\n<li><strong>Sonography:</strong> Fetal weight has been estimated by combining a number of biometric data, e.g. biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL), using the following formulae:\n<ul>\n<li>Shepard’s formula</li>\n<li>Hadlock’s formula.</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ae395dfdcef14bedb1eec4ec4edde0ffx1280x1373.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2777",
      "difficulty": "hard"
    },
    {
      "text": "A researcher recently found out that the heart muscle has the highest arteriovenous oxygen difference of 120 ml/L. Considering that the lungs absorb 200 ml of O2 per minute from the atmosphere. What is the expected cardiac output?",
      "choices": [
        {
          "id": 1,
          "text": "1.67 L/min"
        },
        {
          "id": 2,
          "text": "5 L/min"
        },
        {
          "id": 3,
          "text": "0.6L/min"
        },
        {
          "id": 4,
          "text": " 4 L/min"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The expected cardiac output is <strong>1.67 L/min.</strong></p>\n<p>Based on the <strong>Fick principle,</strong> cardiac output can be calculated by the following equation:</p>\n<p><strong>Cardiac output (L/min) = (O2 absorbed per minute by the lungs (mL/min)) / (Arterio-venous O2 difference (mL/L of blood)) </strong></p>\n<p>In the given scenario:</p>\n<ul>\n<li>The oxygen consumption of the heart muscle or the arteriovenous difference of the pulmonary artery and the pulmonary vein is <strong>120 ml/L.</strong></li>\n<li>O2 absorbed by the lungs: 200ml/min</li>\n</ul>\n<p>Hence cardiac output = 200 ml/min / 120 ml/L= 1.67 L/min </p>\n<p>Cardiac output is the <strong>amount of blood </strong>pumped by the<strong> heart</strong> into the aorta every minute. The <strong>average</strong> cardiac output is <strong>5L/min</strong> and can be measured by various indirect methods.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2771",
      "difficulty": "hard"
    },
    {
      "text": "A 50-year-old man presents to you with complaints of weight loss, hoarseness of voice, and difficulty in breathing. On direct laryngoscopy, a mass involving both the vocal cords with extension to the subglottis is seen. Cords are immobile and there is no lymph node involvement. A biopsy confirms the diagnosis of glottic carcinoma. What is the next step in the management of this case?",
      "choices": [
        {
          "id": 1,
          "text": "Transoral microsurgery"
        },
        {
          "id": 2,
          "text": "Chemotherapy and radiotherapy"
        },
        {
          "id": 3,
          "text": "Transoral microsurgery and radiotherapy"
        },
        {
          "id": 4,
          "text": "Total laryngectomy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The clinical picture of glottic carcinoma involving immobile vocal cords with extension to the subglottis suggests that the tumour belongs to the <strong>T3 stage</strong>.&nbsp;The treatment of choice is<strong>&nbsp;</strong>concurrent<strong> chemotherapy and radiotherapy.</strong></p>\n<p>TNM classification of glottic carcinoma (American Joint Committee on Cancer, 2002)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Stage</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>T1</td>\n<td>Tumour limited to vocal cord(s) with normal mobility</td>\n</tr>\n<tr>\n<td>T1a</td>\n<td>Tumour limited to one vocal cord</td>\n</tr>\n<tr>\n<td>T1b</td>\n<td>Tumour involves both vocal cords</td>\n</tr>\n<tr>\n<td>T2a</td>\n<td>Tumour extends to supraglottis and/or subglottis, with normal vocal cord mobility</td>\n</tr>\n<tr>\n<td>T2b</td>\n<td>Tumour extends to supraglottis and/or subglottis, with impaired vocal cord mobility</td>\n</tr>\n<tr>\n<td>T3</td>\n<td>Tumour limited to the larynx with vocal cord fixation and/or invades paraglottic space and/or&nbsp; minor thyroid cartilage erosion</td>\n</tr>\n<tr>\n<td>T4a</td>\n<td>Tumour invades thyroid cartilage and/or invades tissue beyond the larynx</td>\n</tr>\n<tr>\n<td>T4b</td>\n<td>Tumour invades prevertebral space, encases carotid artery or invades mediastinal structures</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Treatment of laryngeal cancers:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>T stage</strong></td>\n<td><strong>Treatment</strong></td>\n</tr>\n<tr>\n<td>T1a</td>\n<td>TLM &gt; RT</td>\n</tr>\n<tr>\n<td>T1b (mid-cord lesion)</td>\n<td>RT/TLM &gt; OPL</td>\n</tr>\n<tr>\n<td>T2a</td>\n<td>RT/TLM &gt; OPL</td>\n</tr>\n<tr>\n<td>T2b</td>\n<td>RT&nbsp;&plusmn; CT &gt; TLM</td>\n</tr>\n<tr>\n<td>T3</td>\n<td>CRT</td>\n</tr>\n<tr>\n<td>T4a</td>\n<td>TL&gt; CRT</td>\n</tr>\n<tr>\n<td>T4b</td>\n<td>Palliative management</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>TLM: Transoral laser microsurgery; RT: Radiotherapy; OPL: Open partial laryngectomy; CT: Chemotherapy; CRT: Chemoradiotherapy, TL: Total laryngectomy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC0559",
      "difficulty": "hard"
    },
    {
      "text": "A 66-year-old man presents with an enlarged, hard, nodular prostate. Further investigations reveal a tumor that has extended through the prostatic capsule to the seminal vesicle. Other adjacent structures are not involved. What is the stage of his disease?",
      "choices": [
        {
          "id": 1,
          "text": "T1"
        },
        {
          "id": 2,
          "text": "T2"
        },
        {
          "id": 3,
          "text": "T3"
        },
        {
          "id": 4,
          "text": "T4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The stage of the tumor&nbsp;that has extended through the <strong>prostatic capsule</strong> to the <strong>seminal vesicle</strong> and not to other adjacent structures is <strong>T3b</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><strong>Staging of prostate carcinoma:</strong></p>\n</td>\n</tr>\n<tr>\n<td>Tx</td>\n<td>Primary tumor cannot be assessed</td>\n</tr>\n<tr>\n<td>T0</td>\n<td>No evidence of primary tumor</td>\n</tr>\n<tr>\n<td>T1</td>\n<td>Clinically inapparent tumor. <strong>Neither palpable nor visible</strong> on imaging</td>\n</tr>\n<tr>\n<td>T1a</td>\n<td>Incidental histologic finding in 5% or less of tissue resected</td>\n</tr>\n<tr>\n<td>T1b</td>\n<td>Incidental histologic findings in more than 5% of tissue resected</td>\n</tr>\n<tr>\n<td>T1c</td>\n<td>Tumor identified by needle biopsy (for example, because of elevated PSA level)</td>\n</tr>\n<tr>\n<td>T2</td>\n<td>\n<p>Tumor <strong>confined within</strong> <strong>the prostate</strong></p>\n</td>\n</tr>\n<tr>\n<td>T2a</td>\n<td>\n<p>Tumor involves one-half of one lobe or less</p>\n</td>\n</tr>\n<tr>\n<td>T2b</td>\n<td>\n<p>Tumor involves more than one-half of one lobe but not both lobes</p>\n</td>\n</tr>\n<tr>\n<td>T2c</td>\n<td>\n<p>Tumor involves both lobes</p>\n</td>\n</tr>\n<tr>\n<td>T3</td>\n<td>\n<p>Tumors <strong>extend through the prostate capsule</strong></p>\n</td>\n</tr>\n<tr>\n<td>T3a</td>\n<td>Extracapsular extension (unilateral or bilateral)</td>\n</tr>\n<tr>\n<td>T3b</td>\n<td>\n<p>Tumor invades seminal vesicle(s)</p>\n</td>\n</tr>\n<tr>\n<td>T4</td>\n<td>Tumor is fixed or<strong> invades adjacent structures other than seminal vesicles</strong>, such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC0082",
      "difficulty": "medium"
    },
    {
      "text": "In a study, group A received a placebo while group B received a new drug. In group A,  36 deaths were reported out of a sample of 120. In group B, 26 deaths were reported out of a sample size of 130. Calculate the Absolute Risk Reduction (ARR) value.",
      "choices": [
        {
          "id": 1,
          "text": "20%"
        },
        {
          "id": 2,
          "text": "10%"
        },
        {
          "id": 3,
          "text": "15%"
        },
        {
          "id": 4,
          "text": "40%"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div>The<strong> </strong>value of <strong>Absolute Risk Reduction(ARR) </strong>in the given question is 10%.</div>\n<div> </div>\n<div>The <strong>ARR(</strong><strong>Absolute Risk Reduction) </strong><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">is the <strong>difference</strong> in the <strong>absolute risk rates</strong> between the placebo group and the drug group. It </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">is usually expressed in percentages.</span></div>\n<div>Absolute Risk rate= <span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\">No. </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">of deaths/ sample population) x 100.</span></div>\n<div> </div>\n<div><strong><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Calculation:</span></strong></div>\n<div><span class=\"ace-all-bold-hthree\"><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>Step 1:</strong> Calculation of absolute risk rate</span></span></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">The absolute risk rate in </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>group A </strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\"><strong>(placebo)</strong></span></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">= </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\">(36/120)x100</span></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">= </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>30%</strong></span></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">The absolute risk rate in </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>group B </strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\"><strong>(new </strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>drug)</strong></span></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">= </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\">(26/130)x100</span></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">= </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>20%</strong></span></div>\n<div> </div>\n<div><span class=\"ace-all-bold-hthree\"><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>Step 2: </strong>Calculation of absolute risk reduction </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\">(ARR) </span></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">= Absolute risk rate in group A - Absolute risk rate in group B</span></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">= 30 - 20</span></div>\n<div><span class=\"ace-all-bold-hthree\"><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>= 10%</strong></span></span></div>\n<div>Therefore the <strong>Absolute Risk Reduction </strong>in Group B as compared to the placebo group is <strong>10%.</strong></div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">The Absolute Risk Reduction(ARR) signifies the proportion of people who benefitted from the new treatment/intervention over the existing treatment/placebo.</span></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2773",
      "difficulty": "medium"
    },
    {
      "text": "A 12-year-old child weighing 40 Kg involved in a fire accident presented to the emergency room with 40% TBSA third-degree burns. What is the rate of initial fluid resuscitation required in this patient?<div class='question-desc-html'><p>TBSA-Total body surface area</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "0.8 L over 8 hours, followed by 0.8 L over 16 hours"
        },
        {
          "id": 2,
          "text": "1.6 L over 8 hours, followed by 1.6 L over 16 hours"
        },
        {
          "id": 3,
          "text": "2.4 L over 8 hours, followed by 2.4 L over 16 hours"
        },
        {
          "id": 4,
          "text": "3.2 L over 8 hours, followed by 3.2 L over 16 hours"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The rate of initial fluid resuscitation required in this patient is 2.4 L over 8 hours, followed by 2.4 L over 16 hours.</p>\n<p>As per the recent update in Advanced Trauma Life Support (ATLS) 10th edition (2018),  the fluid resuscitation in a pediatric patient <strong>&lt; 14 years age</strong> is:</p>\n<p><strong>Percentage of burn x body weight (kg) x 3 = volume in ml</strong></p>\n<p>In this case, (percentage of burn) 40 x (body weight in kg) 40 x 3 = <strong>4800ml</strong></p>\n<p>The volume in ml is 4800. Therefore volume in liters is 4.8 liters.</p>\n<p>Half of the fluid is given in the first 8 hours of burns and the rest half in the next 16 hours.</p>\n<p>Hence <strong>2.4 litres</strong> has to be given in the <strong>first 8 hours,</strong> followed by <strong>2.4 litres </strong>in the <strong>next 16 hours. </strong></p><p>#<strong>RecentUpdate</strong>: The initial fluid rate used for burns resuscitation has been updated by the American Burn Association to reflect concerns about over-resuscitation when using the traditional Parkland formula. According to the 10th Edition of ATLS (2018), fluid resuscitation in a <strong>pediatric patient &lt; 14 years</strong> should begin at<strong> 3 ml of lactated Ringer’s x patient’s body weight in kg x % TBSA</strong> for second and third-degree burns. </p>\n<p>Note:</p>\n<ul>\n<li>The superficial/1st-degree burns are not considered for the formula. Only the % TBSA of 2nd and 3rd-degree burns is calculated for the formula.</li>\n<li>If the patient is &lt; 1 year or &lt; 30 kg body weight, then the fluid resuscitation will be <strong>3 ml of lactated Ringer's lactate x patient's body weight in kg x % TBSA </strong>along with <strong>5% dextrose at a maintenance rate.</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2853",
      "difficulty": "hard"
    },
    {
      "text": "Which classification system is shown in the image below that is used to stage gastric cancer?",
      "choices": [
        {
          "id": 1,
          "text": "AJCC"
        },
        {
          "id": 2,
          "text": "Japanese classification system"
        },
        {
          "id": 3,
          "text": "Bormann's classification"
        },
        {
          "id": 4,
          "text": "Hinchey classification"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p> The image shows <strong>Bormann classification </strong>used for advanced gastric cancer.</p>\n<p> Gastric carcinoma can be classified as early gastric cancer and advanced gastric cancer.</p>\n<ul>\n<li><strong>Early gastric cancer</strong> involves mucosa, submucosa with or without lymph node involvement. Early gastric cancer can be further classified using the <strong>Japanese classification</strong>.</li>\n<li><strong>Advanced gastric cancer</strong> involves the muscularis layer, with or without adjacent structures. Its macroscopic appearances have been classified using <strong>Bormann classification.</strong></li>\n</ul>\n<p>The given image shows the pathological types of early gastric cancer as per <strong>Japanese system.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/796f18c2bd4b44ddbd9042bef9aa93cdx600x1110.JPEG\" alt=\"Explanation Image\"><p>Other options:</p>\n<p><strong>Option A: AJCC</strong> (American Joint Committee on Cancer) is for squamous cell carcinoma. It is classified based on the extent of differentiation. </p>\n<p><strong>Option D: Hinchey classification</strong><span><strong> </strong></span>is used for <strong>diverticulitis</strong>.</p><hr><h3>Related Pearl: Borrmann’s classification of stomach cancer</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/04a311c018f74fe285d9bc219991b802x1280x1629.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/abb3dbb4cd124791bcbab65a64a12561.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FB4072",
      "difficulty": "medium"
    },
    {
      "text": "Calculate the anion gap from the following values:\nNa+ = 137 mmol/L\nK+ = 4 mmol/L\nCl- = 100 mmol/L\nHCO3- = 15 mmol/L",
      "choices": [
        {
          "id": 1,
          "text": "22 mmol/L"
        },
        {
          "id": 2,
          "text": "16 mmol/L"
        },
        {
          "id": 3,
          "text": "10 mmol/L"
        },
        {
          "id": 4,
          "text": "12 mmol/L"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The anion gap is the <strong>difference between measured cations and measured anions</strong> and is estimated as:</p>\n<p><strong>Anion gap = [Na+] – ([Cl-] + [HCO3-])</strong></p>\n<p>Substituting the given values, AG is 22 mmol/L. <strong>Normal AG</strong> is <strong>6 to 12 mmol/L</strong> with an average of 10 mmol/L.</p>\n<p>The concentrations of anions and cations in plasma must be equal to maintain electrical neutrality. Therefore, there is no real “anion gap” in the plasma.</p>\n<p>However, only certain cations and anions are routinely measured in the clinical laboratory. The <strong>cation normally measured </strong>is<strong> Na+</strong>, and the <strong>anions</strong> are usually <strong>Cl−</strong> and <strong>HCO3−</strong>. The value of plasma potassium is omitted from the calculation of the anion gap.</p>\n<p>Usually, the <strong>unmeasured anions exceed the unmeasured cations</strong>.</p>\n<p>The anion gap will increase if unmeasured anions rise or if unmeasured cations fall.</p>\n<p>The <strong>unmeasured anions</strong> include <strong>albumin</strong>,<strong> phosphate</strong>,<strong> sulfate</strong>, and other organic anions. The <strong>unmeasured cations</strong> include <strong>calcium</strong>,<strong> magnesium</strong>, and<strong> potassium</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2854",
      "difficulty": "medium"
    },
    {
      "text": "A patient underwent laparoscopic cholecystectomy for cholelithiasis. Specimen revealed that she had gall bladder carcinoma infiltrating the muscularis layer. What is the management?",
      "choices": [
        {
          "id": 1,
          "text": "Radical cholecystectomy with adjuvant chemotherapy"
        },
        {
          "id": 2,
          "text": "Adjuvant chemotherapy"
        },
        {
          "id": 3,
          "text": "Extended cholecystectomy"
        },
        {
          "id": 4,
          "text": "Surveillance"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the given clinical scenario, gallbladder carcinoma with T1b lesions is <strong>detected incidentally after cholecystectomy</strong>. Treatment guidelines for the same are as follows:</p>\n<ul>\n<li>Up to stage Ia and stage Ib with negative margins, a standard cholecystectomy would suffice.</li>\n<li>Stage Ib with perineural, lymphovascular invasion, positive cystic duct margins, or poor differentiation, and stage II, extended cholecystectomy should be performed. Extended cholecystectomy involves the removal of the gall bladder, segments IVB and V of the liver, and lymph nodes along the hepatoduodenal ligament, with or without removal of the common bile duct (CBD).</li>\n</ul>\n<p>However, the likelihood of nodal disease increases significantly with T1b lesions and perineural, lymphatic, or vascular invasion, therefore, <strong>extended cholecystectomy</strong> is generally <strong>recommended</strong> for all patients who are <strong>medically fit</strong> with T1b or greater level of invasion.<br /><br />If the initial procedure was performed laparoscopically, the surgeon should examine the laparoscopic port sites. The finding of disease at the port sites is a sign of generalized peritoneal disease and carries a very poor prognosis. However, <strong>resection of port sites</strong> is <strong>no longer recommended.</strong></p>\n<p>Chemotherapy is not required in early gallbladder cancer. Radiation has no role.<strong><br /></strong></p>\n<p><strong>Treatment</strong> of gallbladder carcinoma:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>TNM staging</strong></td>\n<td><strong>Treatment</strong></td>\n</tr>\n<tr>\n<td>T<sub>1a</sub></td>\n<td>Simple cholecystectomy</td>\n</tr>\n<tr>\n<td>T<sub>1b</sub>, T<sub>2</sub>, T<sub>3</sub></td>\n<td>Radical cholecystectomy</td>\n</tr>\n<tr>\n<td>T<sub>4</sub></td>\n<td>Unresectable, chemotherapy and palliative nonsurgical therapy are provided</td>\n</tr>\n<tr>\n<td>N<sub>1</sub></td>\n<td>Regional lymphadenectomy</td>\n</tr>\n<tr>\n<td>N<sub>2</sub></td>\n<td>Radical cholecystectomy plus hepatopancreatic duodenectomy</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC2867",
      "difficulty": "hard"
    },
    {
      "text": "According to the TNM staging, a lung cancer of 2.5 cm is staged as:",
      "choices": [
        {
          "id": 1,
          "text": "T1b"
        },
        {
          "id": 2,
          "text": "T1c"
        },
        {
          "id": 3,
          "text": "T2a"
        },
        {
          "id": 4,
          "text": "T1a"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\">T1c is the T stage of lung carcinoma of size 2.5cm not involving the main bronchus according to TNM staging.</p>\n<table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" colspan=\"2\" valign=\"top\">\n<p class=\"p1\">The international tumor-node-metastasis (TNM) staging system of Lung carcinoma</p>\n<p class=\"p2\"> </p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T: Primary tumor</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p2\"> </p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tx</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Primary tumor cannot be assessed or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T0</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">No evidence of primary tumor</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tis</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Carcinoma in situ</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T1</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumour ≤3 cm in a greatest dimension surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e. not in the main bronchus)</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T1a(mi)</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Minimally invasive adenocarcinoma</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T1a</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumour 1 cm in greatest dimension</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T1b</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumor&gt;1 cm but ≤2 cm in greatest dimension</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\"><strong>T1c</strong></p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\"><strong>Tumor&gt;2 cm but ≤3 cm in greatest dimension</strong></p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T2</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumor&gt;3 cm but ≤5 cm or tumor with any of the following features:c<br />– involves the main bronchus regardless of distance from the carina but without the involvement of the carina<br />– invades visceral pleura<br />– associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T2a</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumor&gt;3 cm but ≤4 cm in greatest dimension</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T2b</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumor&gt;4 cm but ≤5 cm in greatest dimension</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T3</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumor&gt;5 cm but ≤7 cm in greatest dimension or associated with separate tumor nodule(s) in the same lobe as the primary tumor or directly invades any of the following structures: chest wall (including the parietal pleura and superior sulcus tumors), phrenic nerve, the parietal pericardium</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">T4</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tumor&gt;7 cm in greatest dimension or associated with separate tumor nodule(s) in a different ipsilateral lobe than that of the primary tumor or invades any of the following structures: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, and carina</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">N: Regional lymph nodes involvement</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p2\"> </p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Nx</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Regional lymph nodes cannot be assessed</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">N0</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">No regional lymph node metastasis</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">N1</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">N2</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">N3</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">M: Distant metastasis</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p2\"> </p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">M0</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">No distant metastasis</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">M1</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Distant metastasis present</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">M1a</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodule(s) or malignant pleural or pericardial effusion</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">M1b</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Single extrathoracic metastasize</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">M1c</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Multiple extrathoracic metastases in one or more organs</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FA1388",
      "difficulty": "hard"
    },
    {
      "text": "The clearance of a drug which follows first-order kinetics (in one compartment model) is 0.2 L/min and volume of distribution is 40 L. What is the t1/2 of that drug?",
      "choices": [
        {
          "id": 1,
          "text": "140 min"
        },
        {
          "id": 2,
          "text": "220 min"
        },
        {
          "id": 3,
          "text": "240 min"
        },
        {
          "id": 4,
          "text": "180 min"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The t<sub>1/2</sub> of the drug would be 140 minutes.</p>\n<p><strong>t<sub>1/2</sub></strong> is the time required for the plasma concentration or the amount of a drug in the body to be <strong>reduced by 50%</strong>. It depends on its <strong>clearance </strong>and <strong>volume of distribution</strong>. </p>\n<p><strong>t<sub>1/2</sub> = 0.693 x V<sub>d</sub>/Cl</strong></p>\n<p>where V<sub>d</sub> is the volume of distribution and Cl is clearance.</p>\n<p>We can take 0.693 approximately as 0.7.</p>\n<p>V<sub>d</sub> = 40 L</p>\n<p>CL= 0.2 L/min</p>\n<p>Substituting,</p>\n<p>t<sub>1/2</sub> = 0.7 x 40 /0.2</p>\n<p>t<sub>1/2</sub> = 0.7 x 200</p>\n<p>t<sub>1/2</sub> = <strong>140 minutes</strong></p>\n<p>Clinical implications:<strong> Half-life</strong> determines the length of the drug effect. It also indicates whether the accumulation of the drug will occur under a multiple dosage regimen and it is essential to decide on the appropriate dosing interval.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FA4250",
      "difficulty": "hard"
    },
    {
      "text": "A 5-year-old child is brought to you with complaints of noisy breathing. On performing direct laryngoscopy, subglottic stenosis is noted. Which grading system will you use to report the extent of the stenosis?",
      "choices": [
        {
          "id": 1,
          "text": "Hyams grading"
        },
        {
          "id": 2,
          "text": "House Brackmann grading"
        },
        {
          "id": 3,
          "text": "Myer Cotton's grading"
        },
        {
          "id": 4,
          "text": "Modified Mallampati grading"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Myer Cotton&rsquo;s grading</strong> is used for <strong>subglottic stenosis.</strong></p>\n<p>It is the abnormal thickening of cricoid/fibrous tissue proliferation below cords. It causes the airway to narrow and presents with <strong>dyspnea</strong>, <strong>biphasic stridor</strong> and a <strong>normal cry.&nbsp;</strong></p>\n<p>Diagnosis:</p>\n<ul>\n<li>In full-term infants, subglottic diameter &lt;4mm.</li>\n<li>In premature infants, subglottic diameter &lt;3mm.</li>\n</ul>\n<p>The Myer Cotton&rsquo;s grading system allows to stratify the stenosis and plan for treatment:</p>\n<ul>\n<li aria-level=\"1\">Grade 1: &lt;50% stenosis</li>\n<li aria-level=\"1\">Grade 2: 51-70% stenosis</li>\n<li aria-level=\"1\">Grade 3: 71-99% stenosis</li>\n<li aria-level=\"1\">Grade 4: No lumen detected</li>\n</ul>\n<p>Other options</p>\n<p>Option A - <strong>Hyams grading</strong> is a predictive tool used in <strong>olfactory neuroblastoma</strong>.</p>\n<p>Option B - <strong>House Brackmann grading</strong> is used as a <strong>facial nerve grading system.</strong></p>\n<p>Option D - <strong>Modified mallampati</strong> classification is used to <strong>assess difficult airway</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "FC0200",
      "difficulty": "medium"
    }
  ]
}